ScreenerHero
SUPNSupernus Pharmaceuticals, Inc.
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · supernus.com
47.53USD-2.09%Mkt Cap: 2.82B $P/E: —

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
ALM
Almirall, S.A.
$2.46BUSDP/E 37.1

Key Statistics

Company
Market Cap2.82B $
Enterprise Value2.43B $
Revenue (TTM)830.44M $
Gross Profit644.39M $
Net Income (TTM)-38.55M $
Revenue/Share14.46 USD
Last Price47.53 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees778
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS8684591089
Valuation
P/E (Trailing)—
P/E (Forward)10.64
PEG—
EV/EBITDA21.97
EV/Revenue2.92
P/S3.32
P/B2.68
EPS (TTM)-1.88
EPS (Forward)4.46
52W Range
41.7832% of range59.68
52W High59.68 USD
52W Low41.78 USD
Profitability
Gross Margin89.63%
Oper. Margin-2.48%
EBITDA Margin13.30%
Profit Margin-5.36%
ROE-3.63%
ROA-2.65%
Growth
Revenue Growth32.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF47.33M $
CapEx (TTM)1.34M $
FCF Margin10.19%
FCF Yield3.00%
Net Debt-331.90M $
Net Debt/EBITDA-3.01
Balance Sheet
Debt/Equity0.04
Current Ratio2.08
Quick Ratio1.68
Book Value/Sh17.73 USD
Cash/Share6.401 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)61.75 USD
Upside (mean)+29.9%
Target Range55.00 USD – 67.00 USD
$55.00+29.9% to mean$67.00
# Analysts4
Ownership
Shares Out.58.13M
Float51.65M
Insiders4.49%
Institutions106.74%
Short Interest
Short Ratio6.5d
Short % Float10.18%
Short % Out.8.28%
Shares Short4.82M
Short (prev mo.)7.14M
Technical
SMA 5046.68 (+1.8%)
SMA 20048.68 (-2.4%)
Beta0.56
S&P 52W Chg18.16%
Avg Vol (30d)867.71K
Avg Vol (10d)637.42K
Technical Indicators
RSI (14)56.7
MACD0.3561
MACD Signal0.1150
MACD Hist.+0.2411
BB Upper49.35 USD
BB Middle46.82 USD
BB Lower44.30 USD
BB Width10.78%
ATR (14)1.919 USD
Vol Ratio (20d)0.85x